ATE184483T1 - Spirooxathiolan-quinuclidin-derivat zur behandlung des sjögren-syndroms - Google Patents

Spirooxathiolan-quinuclidin-derivat zur behandlung des sjögren-syndroms

Info

Publication number: ATE184483T1
Authority: AT; Austria
Prior art keywords: spirooxathiolane; quinuclidine; sjögren; syndrome; treatment
Prior art date: 1992-07-10

Application number

AT93305423T

Other languages

English (en)

Inventor

Nobuaki Abe

Yasuyoshi Takeshita

Original Assignee

Snow Brand Milk Products Co Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1992-07-10

Filing date

1993-07-09

Publication date

1999-10-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=16540522&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE184483(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1993-07-09 Application filed by Snow Brand Milk Products Co Ltd filed Critical Snow Brand Milk Products Co Ltd

1999-10-15 Application granted granted Critical

1999-10-15 Publication of ATE184483T1 publication Critical patent/ATE184483T1/de

Links

208000021386 Sjogren Syndrome Diseases 0.000 title abstract 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 abstract 2
125000000217 alkyl group Chemical group 0.000 abstract 2
125000003118 aryl group Chemical group 0.000 abstract 2
150000003839 salts Chemical class 0.000 abstract 2
239000002253 acid Substances 0.000 abstract 1
125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 abstract 1
125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
229910052739 hydrogen Inorganic materials 0.000 abstract 1
239000001257 hydrogen Substances 0.000 abstract 1
125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 1
SBYHFKPVCBCYGV-UHFFFAOYSA-N quinuclidine Chemical compound C1CC2CCN1CC2 SBYHFKPVCBCYGV-UHFFFAOYSA-N 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Ophthalmology & Optometry (AREA)
Immunology (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

AT93305423T 1992-07-10 1993-07-09 Spirooxathiolan-quinuclidin-derivat zur behandlung des sjögren-syndroms ATE184483T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
JP4207485A JP2683783B2 (ja)	1992-07-10	1992-07-10	シェーグレン症候群治療剤

Publications (1)

Publication Number	Publication Date
ATE184483T1 true ATE184483T1 (de)	1999-10-15

Family

ID=16540522

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT93305423T ATE184483T1 (de)	1992-07-10	1993-07-09	Spirooxathiolan-quinuclidin-derivat zur behandlung des sjögren-syndroms

Country Status (15)

Country	Link
US (1)	US5340821A (de)
EP (1)	EP0578511B1 (de)
JP (1)	JP2683783B2 (de)
KR (1)	KR100331046B1 (de)
AT (1)	ATE184483T1 (de)
AU (1)	AU666734B2 (de)
CA (1)	CA2099970C (de)
DE (1)	DE69326395T2 (de)
DK (1)	DK0578511T3 (de)
ES (1)	ES2138613T3 (de)
IL (1)	IL106218A (de)
NO (1)	NO303765B1 (de)
NZ (1)	NZ248099A (de)
TW (1)	TW230750B (de)
ZA (1)	ZA934883B (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2852608B2 (ja) *	1994-06-27	1999-02-03	雪印乳業株式会社	口腔乾燥症治療剤
US6140374A (en) *	1998-10-23	2000-10-31	Abbott Laboratories	Propofol composition
JP4447685B2 (ja) *	1999-01-14	2010-04-07	第一三共株式会社	皮膚乾燥症治療剤
JP2006070027A (ja) *	2004-08-06	2006-03-16	Dai Ichi Seiyaku Co Ltd	口腔粘膜投与剤
US20110150974A1 (en) *	2004-08-06	2011-06-23	Daiichi Pharmaceutical Co., Ltd.	Agent For Oral Mucosal Administration
AU2005290532A1 (en) *	2004-10-05	2006-04-13	Astellas Pharma Inc.	Pharmaceutical composition for xerophthalmia and xerostomia treatment
EP2275096A3 (de)	2005-08-26	2011-07-13	Braincells, Inc.	Neurogenese durch modulation des Muscarinrezeptors
EP2258357A3 (de)	2005-08-26	2011-04-06	Braincells, Inc.	Neurogenese mit Acetylcholinesterasehemmer
WO2007047978A2 (en)	2005-10-21	2007-04-26	Braincells, Inc.	Modulation of neurogenesis by pde inhibition
EP2314289A1 (de)	2005-10-31	2011-04-27	Braincells, Inc.	Gaba-rezeptor-vermittelte modulation von neurogenese
US20100216734A1 (en)	2006-03-08	2010-08-26	Braincells, Inc.	Modulation of neurogenesis by nootropic agents
US7678808B2 (en)	2006-05-09	2010-03-16	Braincells, Inc.	5 HT receptor mediated neurogenesis
EP2021000A2 (de)	2006-05-09	2009-02-11	Braincells, Inc.	Neurogenese mittels angiotensin-modulation
WO2008030651A1 (en)	2006-09-08	2008-03-13	Braincells, Inc.	Combinations containing a 4-acylaminopyridine derivative
US20100184806A1 (en)	2006-09-19	2010-07-22	Braincells, Inc.	Modulation of neurogenesis by ppar agents
US8143400B2 (en) *	2008-01-10	2012-03-27	Apotex Pharmachem Inc.	Process for the preparation and purification of cis-2-methylspiro(1,3-oxathiolane-5,3′)quiniclidine hydrochloride
US20100216805A1 (en)	2009-02-25	2010-08-26	Braincells, Inc.	Modulation of neurogenesis using d-cycloserine combinations
ES2443847T3 (es)	2009-11-12	2014-02-20	Acacia Pharma Limited	Uso de betanecol para el tratamiento de xerostomía
GB201107533D0 (en)	2011-05-06	2011-06-22	Acacia Pharma Ltd	Formulaiton
CN102846607A (zh) *	2012-04-09	2013-01-02	珠海亿邦制药股份有限公司	一种以盐酸西维美林为活性成分的固体制剂及其应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4001396A (en) *	1971-08-04	1977-01-04	Chinoin Pharmaceutical And Chemical Works Ltd.	Hormonal product extracted from parathyroid gland and process for the preparation thereof
US4110441A (en) *	1974-04-29	1978-08-29	Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt.	Gamma-l-glutamyl cholamine phosphate
US4100271A (en) *	1976-02-26	1978-07-11	Cooper Laboratories, Inc.	Clear, water-miscible, liquid pharmaceutical vehicles and compositions which gel at body temperature for drug delivery to mucous membranes
US4701450A (en) *	1984-03-21	1987-10-20	Akzo N.V.	Steroids for use as immunomodulators
US4855290A (en) *	1985-05-10	1989-08-08	State Of Israel, Represented By Prime Minister's Office, Israel Institute For Biological Research	Derivatives of quinuclidine
US4684727A (en) *	1985-07-29	1987-08-04	Schering Corporation	Zwitterionic 1,8-naphthyridine and pyrazino[2,3-b]pyridine containing compounds useful as anti-allergic, anti-inflammatory and cycloprotective agents
ZA868369B (en) *	1986-01-10	1987-11-25	Israel State	Derivatives of quinuclidine
GB8717446D0 (en) *	1987-07-23	1987-08-26	Merck Sharp & Dohme	Chemical compounds
US4876260A (en) *	1987-10-28	1989-10-24	State Of Israel, Israel Institute Of Biological Research	Oxathiolanes
CA1303503C (en) *	1987-11-10	1992-06-16	Marc Plamondon	Ophthalmic solution comprising iodine-polyvinylpyrrolidone complex
MX18467A (es) *	1988-11-23	1993-07-01	Pfizer	Agentes terapeuticos de quinuclidinas
US4997654A (en) *	1989-08-14	1991-03-05	Warner-Lambert Company	Method for increasing salivation for xerostomia patients
US5242930A (en) *	1991-02-11	1993-09-07	Merck Sharp & Dohme Ltd.	Azabicyclic compounds, pharmaceutical compositions containing them and their use in therapy

1992
- 1992-07-10 JP JP4207485A patent/JP2683783B2/ja not_active Expired - Lifetime
1993
- 1993-07-02 IL IL10621893A patent/IL106218A/xx not_active IP Right Cessation
- 1993-07-06 TW TW082105361A patent/TW230750B/zh active
- 1993-07-06 KR KR1019930012594A patent/KR100331046B1/ko not_active Expired - Lifetime
- 1993-07-06 CA CA002099970A patent/CA2099970C/en not_active Expired - Lifetime
- 1993-07-07 AU AU41819/93A patent/AU666734B2/en not_active Expired
- 1993-07-07 ZA ZA934883A patent/ZA934883B/xx unknown
- 1993-07-07 NZ NZ248099A patent/NZ248099A/xx not_active IP Right Cessation
- 1993-07-07 US US08/088,304 patent/US5340821A/en not_active Expired - Lifetime
- 1993-07-09 ES ES93305423T patent/ES2138613T3/es not_active Expired - Lifetime
- 1993-07-09 DE DE69326395T patent/DE69326395T2/de not_active Expired - Lifetime
- 1993-07-09 AT AT93305423T patent/ATE184483T1/de active
- 1993-07-09 DK DK93305423T patent/DK0578511T3/da active
- 1993-07-09 EP EP93305423A patent/EP0578511B1/de not_active Expired - Lifetime
- 1993-07-09 NO NO932520A patent/NO303765B1/no not_active IP Right Cessation

Also Published As

Publication number	Publication date
KR940005274A (ko)	1994-03-21
DE69326395D1 (de)	1999-10-21
IL106218A (en)	1997-02-18
DE69326395T2 (de)	2000-04-20
KR100331046B1 (ko)	2002-08-19
IL106218A0 (en)	1993-11-15
CA2099970C (en)	2003-12-30
CA2099970A1 (en)	1994-01-11
TW230750B (de)	1994-09-21
NO303765B1 (no)	1998-08-31
NZ248099A (en)	1999-07-29
JP2683783B2 (ja)	1997-12-03
JPH0624981A (ja)	1994-02-01
AU4181993A (en)	1994-01-13
NO932520L (no)	1994-01-11
NO932520D0 (no)	1993-07-09
EP0578511B1 (de)	1999-09-15
ES2138613T3 (es)	2000-01-16
DK0578511T3 (da)	2000-04-03
US5340821A (en)	1994-08-23
ZA934883B (en)	1994-02-03
EP0578511A1 (de)	1994-01-12
AU666734B2 (en)	1996-02-22

Legal Events

Date	Code	Title	Description
2009-06-15	EEIH	Change in the person of patent owner

Publication	Publication Date	Title
DE69326395D1 (de)	1999-10-21	Spirooxathiolan-quinuclidin-Derivat zur Behandlung des Sjögren-Syndroms
ATE103812T1 (de)	1994-04-15	Zusammensetzung zur behandlung von ischaemischen stoerungen in organen.
DK0493608T3 (da)	1996-02-19	Quinoloncarboxylsyrederivat
HU9603433D0 (en)	1997-02-28	Novel 4-6-diaryl-pyrimidine-derivatives and salts thereof
ATE74608T1 (de)	1992-04-15	Chinolincarbonsaeure-derivate.
ATE79257T1 (de)	1992-08-15	Verwendung von tetrahydrobenz(c,d>indol-6carboxamiden zur herstellung von arzneimitteln zur behandlung von angstzustaenden.
NO982873D0 (no)	1998-06-19	1-metylkarbapenemderivater
DE69209128D1 (de)	1996-04-25	Verwendung von Indazol-Methoxyalkansäure zur Herstellung eines Arzneimittels zur Behandlung von Autoimmunkrankheiten
DE69828197D1 (de)	2005-01-20	Amidderivate zur behandlung neurodegenerativer erkrankungen der netzhaut
DE69123757D1 (de)	1997-01-30	Epoxysuccinamidsäurederivat
DK0420224T3 (da)	1993-04-05	Anthihepatopatisk middel
DE69411852D1 (de)	1998-08-27	Indolderivate, ihre Salze und sie enthaltende Arzneimittel zur Behandlung von Herzkrankheiten
ATE212842T1 (de)	2002-02-15	Quinoxalin-derivate zur behandlung von tinnitus
DE69532963D1 (de)	2004-06-03	Verwendung von 4-acylaminopyridin derivaten zur Herstellung eines Medikaments für die Behandlung von zerebrovaskulären Erkrankungen
DE3884878D1 (de)	1993-11-18	Uricosuretische Zusammensetzung.
DE3782229D1 (de)	1992-11-19	Verwendung von 2-oxo-imidazolidin-derivaten zur behandlung von nierenkrankheiten.
ATE103490T1 (de)	1994-04-15	Derivate der p-guanidinobenzoesaeure zur behandlung der zerebrovaskulaeren kontraktion.
DE69424677D1 (de)	2000-06-29	Präparat zur behandlung der drogenabhängigkeit